About this Journal Submit a Manuscript Table of Contents
Gastroenterology Research and Practice
Volume 2012 (2012), Article ID 674324, 5 pages
http://dx.doi.org/10.1155/2012/674324
Clinical Study

Comparison between Single-Dose Esomeprazole- and Pantoprazole-Based Triple Therapy on the Effectiveness for Helicobacter pylori Eradication in Taiwanese Population

1Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
2Department of Internal Medicine, Pingtung Hospital, Department of Health, Pingtung, Taiwan
3Cancer Center, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
4Department of Medicine, Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
5Department of Gynecology and Obstetrics, E-Da Hospital, I-Shou University, Kaohsiung, Taiwan
6Division of Gastroenterology, Department of Internal Medicine, Buddhist Tzu Chi Hospital and Tzu Chi University, Hualien, Taiwan
7Division of Infectious Diseases, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan

Received 14 March 2012; Accepted 3 May 2012

Academic Editor: Ping-I Hsu

Copyright © 2012 Hsiang-Yao Shih et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background and Study Aims. To compare the effectiveness of two regimens, single-dose esomeprazole- and pantoprazole-based triple therapy, for Helicobacter pylori (H. pylori) eradication. Patients and Methods. A total of 453 patients were enrolled for H. pylori eradication. They were randomly assigned to either EAC group (Esomeprazole 40 mg once daily, Amoxicillin 1 g twice daily, Clarithromycin 500 mg twice daily for 7 days) or PAC group (Pantoprazole 40 mg twice daily, Amoxicillin 1 g twice daily, Clarithromycin 500 mg twice daily for 7 days). Follow-up endoscopy or urea breath test was scheduled 12–16 weeks after the eradication to evaluate the therapeutic response. Results. Higher eradication rate in EAC group than PAC group was shown by intention-to-treat analysis (EAC 72% versus PAC 55%, 𝑃 < 0 . 0 5 ) and per-protocol analysis (EAC 91% versus PAC 72%, 𝑃 < 0 . 0 5 ). The incidence of adverse effects (EAC 19% versus PAC 17%, 𝑃 = 0 . 7 1 2 ) and the compliance (EAC 87% versus PAC 91%, 𝑃 = 0 . 0 8 3 ) were comparable between these 2 groups. Conclusions. Single-dose esomeprazole-based triple therapy is effective for H. pylori eradication.